[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE255421T1 - Polyethylene glycol-interferon alpha konjugate für therapie der infektionen - Google Patents

Polyethylene glycol-interferon alpha konjugate für therapie der infektionen

Info

Publication number
ATE255421T1
ATE255421T1 AT98919777T AT98919777T ATE255421T1 AT E255421 T1 ATE255421 T1 AT E255421T1 AT 98919777 T AT98919777 T AT 98919777T AT 98919777 T AT98919777 T AT 98919777T AT E255421 T1 ATE255421 T1 AT E255421T1
Authority
AT
Austria
Prior art keywords
infections
therapy
polyethylene glycol
interferon alpha
alpha conjugates
Prior art date
Application number
AT98919777T
Other languages
English (en)
Inventor
Paul Glue
David L Cutler
Melton B Affrime
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE255421T1 publication Critical patent/ATE255421T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT98919777T 1997-04-29 1998-04-28 Polyethylene glycol-interferon alpha konjugate für therapie der infektionen ATE255421T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/839,101 US5908621A (en) 1995-11-02 1997-04-29 Polyethylene glycol modified interferon therapy
PCT/US1998/007634 WO1998048840A1 (en) 1997-04-29 1998-04-28 Polyethylene glycol-interferon alpha conjugates for therapy of infection

Publications (1)

Publication Number Publication Date
ATE255421T1 true ATE255421T1 (de) 2003-12-15

Family

ID=25278858

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98919777T ATE255421T1 (de) 1997-04-29 1998-04-28 Polyethylene glycol-interferon alpha konjugate für therapie der infektionen

Country Status (26)

Country Link
US (3) US5908621A (de)
EP (1) EP0975369B1 (de)
JP (1) JP2001524110A (de)
KR (1) KR20010020355A (de)
CN (1) CN1261806A (de)
AR (1) AR012614A1 (de)
AT (1) ATE255421T1 (de)
AU (1) AU7249098A (de)
BR (1) BR9809425A (de)
CA (1) CA2288038C (de)
CO (1) CO4940414A1 (de)
DE (1) DE69820247T2 (de)
DK (1) DK0975369T3 (de)
ES (1) ES2207830T3 (de)
HU (1) HUP0003131A2 (de)
ID (1) ID22977A (de)
IL (1) IL132582A0 (de)
MY (1) MY133891A (de)
NO (1) NO995263L (de)
NZ (1) NZ500763A (de)
PE (1) PE72799A1 (de)
PL (1) PL336576A1 (de)
PT (1) PT975369E (de)
SK (1) SK149199A3 (de)
WO (1) WO1998048840A1 (de)
ZA (1) ZA983543B (de)

Families Citing this family (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
CA2236591C (en) 1995-11-02 2012-01-03 Schering Corporation Continuous low-dose cytokine infusion therapy
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US6753165B1 (en) * 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
JP2001510033A (ja) * 1997-07-14 2001-07-31 ボルダー バイオテクノロジー， インコーポレイテッド 成長ホルモンおよび関連タンパク質の誘導体
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
AU746648B2 (en) * 1997-09-18 2002-05-02 F. Hoffmann-La Roche Ag Use of IFN-alpha and amantadine for the treatment of chronic hepatitis C
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6180096B1 (en) 1998-03-26 2001-01-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
WO1999048535A1 (en) * 1998-03-26 1999-09-30 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
ATE216591T1 (de) * 1998-05-15 2002-05-15 Schering Corp Kombinationstherapie enthaltend ribavirin und interferon alpha bei patienten mit chronischer hepatitis c infektion, die nicht antiviral vorbehandelt sind
ITMI981148A1 (it) * 1998-05-22 1999-11-22 Therapicon Srl Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
ATE307597T1 (de) * 1998-06-08 2005-11-15 Hoffmann La Roche Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
WO2000015210A2 (en) * 1998-09-14 2000-03-23 Vertex Pharmaceuticals Incorporated Use of mycophenol acid and its derivatives for the treatment of virus diseases
ES2447772T3 (es) 1998-10-16 2014-03-12 Biogen Idec Ma Inc. Conjugados de polialquilenglicol de interferón beta-1a y sus usos
JP4761621B2 (ja) 1998-10-16 2011-08-31 バイオジェン・アイデック・エムエイ・インコーポレイテッド インターフェロン−β融合タンパク質および使用
AU2157000A (en) * 1998-12-18 2000-07-12 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
PE20001548A1 (es) * 1999-03-02 2001-01-16 Schering Corp Uso de interferon alfa pegilado para el tratamiento de vih-1
US6362162B1 (en) 1999-04-08 2002-03-26 Schering Corporation CML Therapy
US6605273B2 (en) 1999-04-08 2003-08-12 Schering Corporation Renal cell carcinoma treatment
NZ514417A (en) * 1999-04-08 2003-10-31 Schering Corp Use of pegylated interferon alpha in chronic myeloid leukemia (CML) therapy
DK1043026T3 (da) * 1999-04-08 2005-07-04 Schering Corp Melanombehandling
PT1043025E (pt) * 1999-04-08 2005-09-30 Schering Corp Tratamento de carcinoma da celula renal
US6923966B2 (en) * 1999-04-08 2005-08-02 Schering Corporation Melanoma therapy
HUP0202734A3 (en) * 1999-05-04 2003-11-28 Schering Corp Use of pegylated interfron alfa-ccr5 antagonist combination for hiv therapy
US6635646B1 (en) * 1999-05-04 2003-10-21 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
BR0013252A (pt) * 1999-08-13 2002-04-16 Hoffmann La Roche Micofenolato mofetila em associação com peg-ifn-alfa
AU1494801A (en) * 1999-09-29 2001-04-30 Cleveland Clinic Foundation, The Therapy with 2-5a and interferon
JP2001288109A (ja) * 2000-04-06 2001-10-16 Schering Plough Corp 黒色腫治療
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
AP2006003708A0 (en) * 2000-05-26 2006-08-31 Idenix Cayman Ltd Methods and compositions for treating flavivirusesand pestiviruses
DE60121449T2 (de) * 2000-08-07 2007-02-01 Sciclone Pharmaceuticals, Inc., San Mateo Behandlung von hepatitis c mit thymosin und pegyliertem interferon
US7208167B2 (en) * 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
ES2367891T3 (es) 2000-09-29 2011-11-10 Schering Corporation Interleucina-10 pegilada.
JP4220235B2 (ja) * 2000-11-03 2009-02-04 インターシア セラピューティクス，インコーポレイティド 短期及び長期の薬剤薬量決定のための方法
WO2002044717A1 (en) * 2000-12-01 2002-06-06 Cornell Research Foundation Animal model for flaviviridae infection
AU2002220257A1 (en) * 2000-12-07 2002-06-18 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
US6720000B2 (en) 2001-03-19 2004-04-13 Three Rivers Pharmaceutical, Llc Process for producing wet ribavirin pellets
WO2003026589A2 (en) * 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
MXPA04003238A (es) * 2001-10-05 2004-07-08 Intermune Inc Metodo para tratar la infeccion de virus de hepatitis con una configuracion de suministro de interferon multifasica.
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
AU2002350082B9 (en) * 2001-11-02 2006-08-31 Sandoz Inc. Process for preparing quick dissolving, high loading ribavirin compositions
DE60237721D1 (de) * 2001-11-09 2010-10-28 Intarcia Therapeutics Inc Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
KR100480429B1 (ko) * 2001-12-04 2005-04-06 선바이오(주) 인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
US20050095224A1 (en) * 2001-12-07 2005-05-05 Ramachandran Radhakrishnan Compositions and method for treating hepatitis virus infection
CA2753899C (en) * 2002-01-18 2014-03-25 Biogen Idec Ma Inc. Polyalkylene glycol with moiety for conjugating biologically active compounds
BR0307712A (pt) * 2002-02-14 2005-05-24 Pharmasset Ltd Composto, composição e uso dos mesmos no tratamento de infecções por flaviviridae e proliferação celular anormal
JP2005533000A (ja) * 2002-03-05 2005-11-04 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム Ｍｄａ−７に関与する免疫誘導を増強する方法
WO2003101199A1 (en) * 2002-05-31 2003-12-11 Schering Corporation Combination therapy for rna virus infections involving ribavirin and impdh inhibitors
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CN100348607C (zh) 2002-06-28 2007-11-14 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒科病毒感染的2’和3’－核苷前药
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
RS113904A (en) * 2002-06-28 2007-02-05 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
JP4181543B2 (ja) 2002-08-31 2008-11-19 シージェイチェイルジェダンコーポレーション 糖鎖化ヒトインターフェロンアルファ同種体
US7538094B2 (en) * 2002-09-19 2009-05-26 Three Rivers Pharmacueticals, Llc Composition containing ribavirin and use thereof
AU2003295395A1 (en) * 2002-11-04 2004-06-07 4Life Research, Lc Compositions, systems, and methods for focusing a cell-mediated immune response
ES2624353T3 (es) * 2002-11-15 2017-07-13 Idenix Pharmaceuticals Llc 2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
EP1562895A1 (de) 2002-11-19 2005-08-17 Achillion Pharmaceuticals, Inc. Subsitiuierte arylacylthioharstoffe und ähnliche verbindungen; inhibitoren der viralen replikation
PL377376A1 (pl) 2002-11-25 2006-02-06 Sciclone Pharmaceuticals, Inc. Sposoby ochrony przed uszkodzeniem przez promieniowanie z użyciem Ó-tymozyny
ES2470771T3 (es) * 2002-12-12 2014-06-24 Idenix Pharmaceuticals, Inc Procedimiento para la producción de nucle�sidos ramificados en 2'
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0301879D0 (en) * 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
WO2004078194A1 (en) * 2003-02-28 2004-09-16 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
US20070077225A1 (en) * 2003-02-28 2007-04-05 Blatt Lawrence M Continuous delivery methods for treating hepatitis virus infection
US20060134801A1 (en) * 2003-03-03 2006-06-22 Board Of Regents, The University Of Texas System Methods and compositions involving MDA-7
US20070154454A1 (en) * 2003-03-28 2007-07-05 Brian Murphy Compositions and methods for treating poxvirus infection
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
EP1633766B1 (de) 2003-05-30 2019-03-06 Gilead Pharmasset LLC Modifizierte fluorinierte nukleosidanaloga
GB0320638D0 (en) 2003-09-03 2003-10-01 Novartis Ag Organic compounds
RS20110578A3 (en) 2003-10-14 2016-02-29 F. Hoffmann-La Roche Ltd MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULPHONAMIDES AS HCV REPLICATION INHIBITORS
WO2005082396A2 (en) * 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
GB0500020D0 (en) 2005-01-04 2005-02-09 Novartis Ag Organic compounds
NZ548256A (en) 2004-02-02 2010-02-26 Ambrx Inc Modified human four helical bundle polypeptides and their uses
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
CN100355784C (zh) * 2004-02-12 2007-12-19 江苏恒瑞医药股份有限公司 聚乙二醇修饰α－干扰素1b的制备方法
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
CN1980657A (zh) 2004-05-05 2007-06-13 耶鲁大学 新颖的抗病毒赛菊宁黄质类似物
MXPA06013050A (es) * 2004-05-14 2007-03-28 Sciclone Pharmaceuticals Inc Composiciones a base de compuestos inmunoreguladores para el tratamiento o prevencion de infecciones virales respiratorias.
PL1778272T3 (pl) * 2004-07-14 2011-07-29 Novartis Ag Zastosowanie kombinacji cyklosporyny i pegylowanych interferonów do leczenia zapalenia wątroby typu C (HCV)
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
BRPI0513332A (pt) 2004-08-12 2008-05-06 Schering Corp formulação de interferon peguilado estável
ES2769377T3 (es) * 2004-09-14 2020-06-25 Gilead Pharmasset Llc Intermedios de D-ribonolactona con sustitución de 2-fluoro-2-alquilo
WO2006056464A2 (en) 2004-11-26 2006-06-01 Pieris Ag Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
NZ555143A (en) * 2004-12-23 2009-12-24 Novartis Ag Compositions for HCV treatment
KR20070089954A (ko) * 2004-12-23 2007-09-04 노파르티스 아게 플라비비리대 치료용 화합물
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US8052996B2 (en) 2005-02-03 2011-11-08 Intarcia Therapeutics, Inc. Two-piece, internal-channel osmotic delivery system flow modulator
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
CN101166539B (zh) * 2005-02-08 2012-01-04 得克萨斯大学体系董事会 用于治疗癌症的涉及mda-7的组合物和方法
ES2302402B1 (es) * 2005-06-16 2009-05-08 Proyecto De Biomedicina Cima, S.L. Uso de una citoquina de la familia de interleuquina-6 en la preparacion de una composicion para administracion combinada con interferon-alfa.
AU2006259348B2 (en) 2005-06-17 2010-07-22 Novartis Ag Use of sanglifehrin in HCV
US7695710B2 (en) * 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
EP1901777A2 (de) * 2005-06-20 2008-03-26 Pepgen Corporation Lang zirkulierende chimären mit niedriger toxizität von humanen interferon-alpha-analoga und interferon tau
JP5249028B2 (ja) 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
NZ568135A (en) 2005-10-11 2011-06-30 Array Biopharma Inc Macrocyclic compounds and methods for inhibiting hepatitis C viral replication
EP1976382B1 (de) * 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Verfahren zur herstellung eines synthetischen zwischenprodukts für die herstellung von verzweigten nukleosiden
JP5046030B2 (ja) 2006-01-12 2012-10-10 北里第一三共ワクチン株式会社 インターフェロンαを含む口腔組成物
US20070231301A1 (en) * 2006-03-31 2007-10-04 Warren Stephen L Parenteral low dose type 1 interferons for bladder cancer
UA100666C2 (uk) 2006-04-11 2013-01-25 Новартіс Аг Інгібітори нсv/віл та їх застосування
US8114150B2 (en) * 2006-06-14 2012-02-14 Advanced Cardiovascular Systems, Inc. RGD peptide attached to bioabsorbable stents
AR078117A1 (es) 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
CA2659858A1 (en) 2006-08-02 2008-07-24 United Therapeutics Corporation Liposome treatment of viral infections
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
US20080131398A1 (en) * 2006-08-21 2008-06-05 United Therapeutics Corporation Combination therapy for treatment of viral infections
US8679472B1 (en) 2006-10-05 2014-03-25 Merck, Sharp & Dohme Corp. Crystal of human interferon alpha 2B in complex with zinc
SG175621A1 (en) * 2006-10-12 2011-11-28 Novartis Ag Use of modified cyclosporins
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
IL290847B2 (en) 2007-04-23 2024-11-01 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and their uses
KR20100019467A (ko) 2007-05-02 2010-02-18 암브룩스, 인코포레이티드 변형된 인터페론 베타 폴리펩티드 및 그의 용도
EP2247743B1 (de) 2008-02-08 2016-04-06 Ambrx, Inc. Modifizierte leptin-polypeptide und deren verwendungen
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
EP2282723A2 (de) * 2008-03-26 2011-02-16 University of Oxford Liposome mit endoplasmischem retikulum als target
TW200946541A (en) * 2008-03-27 2009-11-16 Idenix Pharmaceuticals Inc Solid forms of an anti-HIV phosphoindole compound
LT2279007T (lt) 2008-04-29 2016-10-10 Ascendis Pharma Growth Disorders Division A/S Pegiliuoto rekombinantinio žmogaus augimo hormono junginiai
EP2113256A1 (de) 2008-04-29 2009-11-04 Ascendis Pharma AS Pegylierte rhGH-Verbindungen
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
DK3381933T3 (da) 2008-06-24 2020-08-03 Technische Universität München Muteiner af hngal og relaterede proteiner med affinitet til et givet mål
CA2737376A1 (en) * 2008-09-17 2010-03-25 Boehringer Ingelheim International Gmbh Combination of hcv ns3 protease inhibitor with interferon and ribavirin
ES2655364T3 (es) 2008-12-17 2018-02-19 Merck Sharp & Dohme Corp. Producción de IL-10 mono- y dipegilada y sus usos
CN102325783A (zh) 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
SG172361A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside analogs
SG172359A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside phosphoramidates
EP2412730B1 (de) * 2009-03-27 2014-09-10 JW Pharmaceutical Corporation Mit interferon-alpha- (ifn-alpha-) kondensiertes protein mit ifn-alpha und cytoplasmic transduction peptide (ctp)
EP2410989A2 (de) * 2009-03-27 2012-02-01 The Chancellor, Masters and Scholars of the University of Oxford Liposome zur senkung des cholesterinspiegels
US20110182850A1 (en) 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2459211A1 (de) 2009-07-31 2012-06-06 Medtronic, Inc. Kontinuierliche subkutane verabreichung von interferon an hepatitis-c-patienten
CA2770149A1 (en) 2009-08-05 2011-02-10 Pieris Ag Controlled release formulations of lipocalin muteins
RU2753280C2 (ru) 2009-09-28 2021-08-12 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
SG10201408073XA (en) 2009-12-07 2015-01-29 Pieris Ag Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
MX2012011171A (es) 2010-03-31 2013-02-01 Gilead Pharmasset Llc Fosforamidatos de nucleosido.
PT2580236T (pt) 2010-06-08 2019-05-30 Astrazeneca Ab Muteínas da lipocalina de lágrima, que se ligam ao recetor-alfa da il-4
US20120123338A1 (en) 2010-06-16 2012-05-17 Medtronic, Inc. Damping systems for stabilizing medications in drug delivery devices
BR112012033022A2 (pt) 2010-06-24 2016-12-20 Genosciense Pharma Sas tratamento de vírus de hepatite c relacionado a doenças utilizando hidroxicloroquina ou uma combinação de hidroxicloroquina e um agente antiviral
RU2625011C2 (ru) 2010-08-16 2017-07-11 Пиерис АГ Белки, связывающиеся с гепсидином
CN103179974A (zh) 2010-10-05 2013-06-26 诺华有限公司 丙型肝炎病毒感染的新疗法
MX2013003945A (es) 2010-10-08 2013-06-05 Novartis Ag Formulaciones de vitamina e como inhibidoras de sulfamida ns3.
CA2817779C (en) 2010-11-15 2019-02-19 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
RU2013129824A (ru) 2010-11-30 2015-01-10 Новартис Аг Новое лечение инфекции вируса гепатита с
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
DK2646552T3 (en) 2010-12-02 2017-10-23 Pieris Pharmaceuticals Gmbh MUTEINES OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR CTLA-4
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
RU2013148539A (ru) 2011-03-31 2015-05-10 Новартис Аг Алиспоривир для лечения инфекции вируса гепатита с
MX2013011411A (es) 2011-04-01 2014-04-14 Novartis Ag Tratamiento para infeccion por el virus de hepatitis b solo o en combinacion con el virus de hepatitis delta y enfermedades hepaticas asociadas.
SG193908A1 (en) 2011-04-13 2013-11-29 Novartis Ag Treatment of hepatitis c virus infection with alisporivir
AU2012314517A1 (en) 2011-09-27 2014-04-17 Novartis Ag Alisporivr for treatment of Hepatis C virus infection
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
CA2858962C (en) 2011-12-13 2023-09-05 Pieris Ag Compositions of human tear lipocalin muteins and methods of use thereof
US8809354B2 (en) 2011-12-31 2014-08-19 Sheikh Riazuddin 3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
JP2015509980A (ja) 2012-03-14 2015-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
JP2015512900A (ja) 2012-03-28 2015-04-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法
US9522940B2 (en) 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
EP2920202B1 (de) 2012-11-19 2018-08-29 Pieris Pharmaceuticals GmbH Neue spezifisch bindende polypeptide und ihre verwendung
WO2014140210A1 (en) 2013-03-14 2014-09-18 Pieris Ag Novel binding proteins for pcsk9
EP2986306A4 (de) 2013-04-18 2016-12-07 Armo Biosciences Inc Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden
EP3010527B1 (de) 2013-06-17 2018-08-08 Armo Biosciences, Inc. Verfahren zur beurteilung der proteinidentität und -stabilität
KR102239196B1 (ko) 2013-08-27 2021-04-12 길리애드 파마셋 엘엘씨 2종의 항바이러스 화합물의 조합 제제
CA2920679A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20160079114A (ko) 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
EP3094650A2 (de) 2014-01-13 2016-11-23 Pieris Pharmaceuticals GmbH Multispezifisches polypeptid für lokalisierte tumorimmunmodulation
DK3145945T3 (da) 2014-05-22 2020-09-28 Pieris Pharmaceuticals Gmbh Hidtil ukendte specifikt bindende polypeptider og anvendelser deraf
US10293043B2 (en) 2014-06-02 2019-05-21 Armo Biosciences, Inc. Methods of lowering serum cholesterol
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MX2017004838A (es) 2014-10-14 2017-10-16 Armo Biosciences Inc Composiciones de interleucina-15 y usos de estas.
CA2963995A1 (en) 2014-10-22 2016-04-28 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
IL251906B2 (en) 2014-11-18 2024-04-01 Ascendis Pharma Endocrinology Div A/S Novel polymeric human growth hormone drug matrices
PT3220892T (pt) 2014-11-21 2021-11-05 Ascendis Pharma Endocrinology Div A/S Formas de dosagem de hormona do crescimento de longa ação
WO2016120307A1 (en) 2015-01-28 2016-08-04 Pieris Ag Novel proteins specific for angiogenesis
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
TN2017000348A1 (en) 2015-02-18 2019-01-16 Sanofi Sa Novel proteins specific for pyoverdine and pyochelin
CN114316067A (zh) 2015-05-04 2022-04-12 皮里斯制药有限公司 抗癌融合多肽
CN107820500B (zh) 2015-05-04 2022-03-01 皮里斯制药有限公司 Cd137特异性的蛋白
EP4219535A1 (de) 2015-05-18 2023-08-02 Pieris Pharmaceuticals GmbH Antikrebsfusionspolypeptid
EP3298029A1 (de) 2015-05-18 2018-03-28 Pieris Pharmaceuticals GmbH Muteine von menschlichem lipocalin 2 mit affinität für glypican-3 (gpc3)
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
CN107920884B (zh) 2015-06-03 2021-08-27 因塔西亚制药公司 植入物放置和移除系统
EP3115371A1 (de) 2015-07-07 2017-01-11 Sanofi Fusionsmoleküle
US10501510B2 (en) 2015-07-15 2019-12-10 Pieris Pharmaceuticals Gmbh Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereof
JP7053453B2 (ja) 2015-08-25 2022-04-12 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためのインターロイキン１０の使用方法
BR112018010887A2 (pt) 2015-11-30 2018-11-21 Pieris Australia Pty Ltd polipeptídeo de fusão
TW201725212A (zh) 2015-12-10 2017-07-16 第一三共股份有限公司 特異性於降鈣素基因相關胜肽的新穎蛋白
WO2017200943A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
EP3471755B1 (de) * 2016-06-20 2020-04-22 Elanco US Inc. Pegyliertes porcines interferon und verfahren zur verwendung davon
WO2018035281A1 (en) 2016-08-17 2018-02-22 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
WO2018087108A1 (en) 2016-11-09 2018-05-17 Pieris Pharmaceuticals Gmbh Proteins specific for cd137
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
CN110402252A (zh) 2017-01-18 2019-11-01 皮里斯制药有限公司 对lag-3具有结合亲和力的脂质运载蛋白突变蛋白
MD3830120T3 (ro) 2018-07-31 2023-11-30 Pieris Pharmaceuticals Gmbh Noi proteine de fuziune specifice pentru CD137 și PD-L1
MA55069A (fr) 2019-02-26 2022-01-05 Pieris Pharmaceuticals Gmbh Nouvelles protéines de fusion spécifique à cd137 et gpc3
JP2023527908A (ja) 2020-06-05 2023-06-30 ピエリス ファーマシューティカルズ ゲーエムベーハー ４－１ｂｂをターゲティングする多量体免疫調節物質
WO2022214649A1 (en) 2021-04-08 2022-10-13 Pieris Pharmaceuticals Gmbh Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
WO2022243341A1 (en) 2021-05-18 2022-11-24 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding affinity for ox40
WO2024064713A1 (en) 2022-09-21 2024-03-28 Seagen Inc. Novel fusion protein specific for cd137 and cd228

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE29835E (en) 1971-06-01 1978-11-14 Icn Pharmaceuticals 1,2,4-Triazole nucleosides
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
NZ217844A (en) 1985-10-11 1989-10-27 Sumitomo Pharma A sustained release pharmaceutical composition containing silicone elastomer and an albumin
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5676942A (en) 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
MX9307733A (es) 1992-12-23 1994-06-30 Schering Corp Restauracion de la funcion inmunologica en pacientes asintomaticos de vih-positivo.
ATE214940T1 (de) * 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5738846A (en) * 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US6387365B1 (en) 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
CA2236591C (en) * 1995-11-02 2012-01-03 Schering Corporation Continuous low-dose cytokine infusion therapy
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
US5849800A (en) 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection

Also Published As

Publication number Publication date
WO1998048840A1 (en) 1998-11-05
NZ500763A (en) 2002-03-01
US5908621A (en) 1999-06-01
SK149199A3 (en) 2000-11-07
ES2207830T3 (es) 2004-06-01
BR9809425A (pt) 2000-07-25
EP0975369A1 (de) 2000-02-02
US6177074B1 (en) 2001-01-23
ZA983543B (en) 1998-11-10
DK0975369T3 (da) 2004-04-05
KR20010020355A (ko) 2001-03-15
AU7249098A (en) 1998-11-24
HUP0003131A2 (hu) 2001-11-28
DE69820247D1 (de) 2004-01-15
DE69820247T2 (de) 2004-09-09
NO995263D0 (no) 1999-10-28
AR012614A1 (es) 2000-11-08
NO995263L (no) 1999-12-27
CN1261806A (zh) 2000-08-02
PE72799A1 (es) 1999-08-06
MY133891A (en) 2007-11-30
PT975369E (pt) 2004-04-30
EP0975369B1 (de) 2003-12-03
IL132582A0 (en) 2001-03-19
CA2288038A1 (en) 1998-11-05
CO4940414A1 (es) 2000-07-24
PL336576A1 (en) 2000-07-03
JP2001524110A (ja) 2001-11-27
CA2288038C (en) 2003-07-29
ID22977A (id) 1999-12-23
US6524570B1 (en) 2003-02-25

Similar Documents

Publication Publication Date Title
ATE255421T1 (de) Polyethylene glycol-interferon alpha konjugate für therapie der infektionen
NO992806D0 (no) Terapeutiske midler
PT892640E (pt) Composicoes farmaceuticas de micofenolato entericamente revestidas
CY2012029I1 (el) Νεα μορφη της s-ομεπραζολης
EE04190B1 (et) Asendatud bensopüraani derivaatide kasutamine põletiku raviks
PT907364E (pt) Composicao farmaceutica de libertacao sustida
ID22878A (id) Komposisi aktif secara terapi
NO980546D0 (no) Farmasöytiske midler
ID18679A (id) Penggunaan terapi lanjutan
DE69731747D1 (de) Peptid derivate
IS4898A (is) Sáraumbúðir
BR9507768A (pt) Composição farmacêutica
ID16838A (id) Komposisi dekafluoropentana
ID18698A (id) Komposisi farmasi
ID21769A (id) Komposisi-komposisi cangkokan hasil kopolimerisasi
ID17419A (id) Komposisi dekafluoropentana
ITMI962628A0 (it) Composizione farmaceutica
EE9700123A (et) Välispidiselt kasutatav põletikuvastane vahend
ATA155395A (de) Funktionelle lumbalbandage
ID20659A (id) Arsitektur kemampuan cache
ID24439A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia
KR950026319U (ko) 치료환자용 팬티
KR960026951U (ko) 자동차의자의 포켓
KR970060346U (ko) 환자용 팬티
BR1100567A (pt) Composição farmacêutica de 3-aminoquinuclidina substituìda

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0975369

Country of ref document: EP